NCT05074966招募中3 期
A Phase III, Multicenter, Open-label, Randomized Study to Assess the Efficacy and Safety of mXELOX Plus Cetuximab Versus FOLFOX Plus Cetuximab in Chinese Patients With RAS and BRAF Wild-type Metastatic Colorectal Cancer
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 314
- 试验地点
- 2
- 主要终点
- median PFS
研究概览
简要总结
This is an open label, multicenter, randomized study in Chinese patients with RAS and BRAF wild-type mCRC. Participants were randomly assigned to cetuximab + FOLFOX (group A) and cetuximab + modified XELOX[mXELOX] (group B). All patients in groups A and B will be treated until progression of disease(PD), death, intolerable toxicity or withdrawal of informed consent, whichever occurs first.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provide written informed consent (ICF) prior to any study procedure.
- •Patient must be ≥18 years of age, at the time of signing the informed consent.
- •Patients who had histologically or cytologically confirmed RAS and BRAF wild-type, initially unresectable metastatic adenocarcinoma of the left-sided colon or rectum, excluding appendiceal or anal cancer.
- •The patients were willing to receive FOLFOX /mXELOX plus cetuximab as the first-line treatment choice after the diagnosis of mCRC;
- •At least one measurable metastatic lesion(s) as defined by RECIST version 1.
- •Eastern Cooperative Oncology Group (ECOG) performance score was 0-1 or KPS score ≥
- •Life expectancy of at least 12 weeks in the opinion of the investigator.
- •Neutrophils ≥ 1.5 × 109 / L, platelet ≥ 75 × 109 / L and hemoglobin ≥ 9 g / dl; Total bilirubin ≤ 1.5 × upper limit of normal value (ULN); ASAT (SGOT) and / or ALAT (SGPT) ≤ 2.5 × UNL (≤5×ULN in case of liver metastases）； Alkaline phosphatase ≤ 2.5 × UNL (≤ 5 × ULN in case of liver metastases; ≤ 10× ULN in case of bone metastasis ）； LDH <1500 U/L; Creatinine clearance (calculated according to Cockcroft and Gault) >60 mL/min or serum creatinine ≤1.5×ULN.
排除标准
- •Previously received chemotherapy for CRC, except for adjuvant therapy>9 months (chemotherapy with oxaliplatin) or >6 months (chemotherapy without oxaliplatin) before the start of the study
- •Patients that has been treated with monoclonal antibody, VEGF pathway targeted therapy, EGFR pathway targeted therapy, or other signal transduction pathway inhibitors
- •Radiotherapy, RFA, interventional therapy or surgery were performed within 28 days before the first medication (except for previous diagnostic biopsy)
- •Other active malignant tumors, excluding those who have been disease free for more than 5 years or in situ cancer considered to have been cured by adequate treatment
- •Brain metastasis or meningeal metastasis has been confirmed. Patients with neurological symptoms should receive brain CT / MRI examination to exclude metastasis
- •Peripheral nerve disorder is above grade 1(NCI CTCAE Version 5 )
- •Existing toxicity or unrecovered toxicity caused by previous treatment whose grade is above 2 according to CTCAE criteria(excluding anemia, alopecia, skin pigmentation)
- •Ascites, pleural effusion or pericardial fluid requiring drainage in the past 4 weeks
- •Patients who is suffering from intestinal obstruction, gastrointestinal bleeding, pulmonary fibrosis or interstitial pneumonia, renal failure, liver failure or cerebrovascular disease
- •Diabetes was not controlled, defined as HbA1c > 7.5% after anti-diabetic drugs or hypertension was not controlled, defined as systolic / diastolic blood pressure > 140 / 90 mmHg after antihypertensive drug
- •Myocardial infarction, severe/unstable angina, New York Heart Association (NYHA) class III or IV congestive heart failure in the past 12 months
- •Patients who was allergic to any of the research drugs (cetuximab, 5-FU, oxaliplatin, capecitabine) in the past
- •Deficiency in dihydropyrimidine dehydrogenase (DPD) as manifested by medical history of fluorouracil adverse reactions
- •Known to be infected with human immunodeficiency virus (HIV), have acquired immunodeficiency syndrome (AIDS) related diseases, have active hepatitis B or hepatitis C
- •Suffering from autoimmune diseases or history of organ transplantation requiring immunosuppressive therapy
- •May increase the risk associated with participation in the study or administration of the study drug or mental illness that may interfere with the interpretation of research results
- •Pregnant women (determined by serum human chorionic gonadotropin [hCG]) or lactating women, or plan to conceive during the treatment period, 2 months after cetuximab treatment and 6 months after capecitabine treatment. Women of childbearing age with positive or no pregnancy test at baseline. Women of childbearing age or sexually active men were not willing to use contraception during the study period, at least 2 months after cetuximab treatment and 6 months after capecitabine treatment. Postmenopausal women must be amenorrhea for at least 12 months to be considered infertile
- •There are other serious diseases that the researchers believe patients cannot be included in the study
结局指标
主要结局
median PFS
时间窗: From Baseline to primary completion date, about 48 months
from randomization to PD or death from any cause
次要结局
- Number of Participants With Electrolyte Abnormalities During Treatment Period(From Baseline to primary completion date, about 48 months)
- Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CR29 (EORTC QLQ-CR29)(From Baseline to primary completion date, about 48 months)
- Number of Participants With Adverse Events（AEs） During Treatment Period(From Baseline to primary completion date, about 48 months)
- Number of Participants With Hematology Abnormalities During Treatment Period(From Baseline to primary completion date, about 48 months)
- Number of Participants With Clinical chemistry Abnormalities During Treatment Period(From Baseline to primary completion date, about 48 months)
- Change From Baseline in 5-level EuroQol-5 Dimensions(EQ-5D-5L)(From Baseline to primary completion date, about 48 months)
- Overall Survival OS(From Baseline to primary completion date, about 48 months)
- objective response rate(From Baseline to primary completion date, about 48 months.)
研究者
Aiping Zhou
Deputy director of Internal Medicine
Chinese Academy of Medical Sciences
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
3 期
Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal CancerColorectal CancerNCT04262635Sun Yat-sen University80
进行中（未招募）
3 期
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal CancerMetastatic Colorectal CancerNCT04854668Chia Tai Tianqing Pharmaceutical Group Co., Ltd.748
终止
3 期
Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal CancerMetastatic Colorectal CancerNCT05223673Institut de Recherches Internationales Servier7
已完成
3 期
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension StudyEsophagogastric Junction CarcinomaEsophageal CarcinomaNCT03933449Merck Sharp & Dohme LLC123
已完成
1 期
Safety of RAD001 in Chinese Patients With Metastatic Renal Cell CancerMetastatic Renal Cell CarcinomaNCT01152801Novartis Pharmaceuticals64